MDS Nordion to Expand Facility to Meet Growing Demand for Medical Imaging Agent in Europe
01 Marzo 2007 - 2:00PM
PR Newswire (US)
Expanded Facility in Fleurus, Belgium to be leading player in
supply of Glucotrace(R) for growing market OTTAWA, March 1
/PRNewswire-FirstCall/ -- MDS Nordion, a leading global provider of
medical isotopes and radiopharmaceuticals for molecular imaging, is
investing U.S. $5.8 million / (euro) 4.5 million to expand its
production facility in Fleurus, Belgium to meet the growing demand
for a medical imaging agent used in cancer diagnosis and treatment.
The agent, Fluorine-18 Fludeoxyglucose or FDG, is marketed and
distributed by MDS Nordion under the name Glucotrace(R).
Glucotrace(R) is used in a highly sensitive medical imaging
technique called PET or Positron Emission Tomography. As cancer
rates continue to rise in Europe, the use of PET is increasing to
diagnose cancer and monitor patient progress while in treatment.
Glucotrace(R) is a time-sensitive diagnostic pharmaceutical with a
limited lifespan. As a result, it is critical to have the ability
to reliably supply Glucotrace(R) to hospitals and clinical sites on
time. With this expansion, MDS Nordion will be able to serve more
customers within France and the Benelux Economic Union (Belgium,
Netherlands and Luxembourg). "The new production facility will give
MDS Nordion the ability to meet increased demand from our current
customers as well as extend our market reach to new customers,"
said Steve West, President of MDS Nordion. "We are committed to
providing a reliable supply of Glucotrace(R) to the medical imaging
community in Europe." Through this investment and capital upgrade,
MDS Nordion will build a larger production centre for Glucotrace(R)
within its existing facilities in Fleurus. The investment will also
optimize MDS Nordion's current resources including a higher
capacity cyclotron to produce FDG. Presently, MDS Nordion produces
Glucotrace(R) as part of a joint venture with the University of
Liege (ULG) about 80 kilometres west of Fleurus. The new MDS
Nordion facility in Fleurus, combined with the existing site at
ULG, will greatly increase production capacity for Europe as well
as provide the necessary manufacturing and supply flexibility to
serve growing market demand. First production of Glucotrace(R) from
the new facility in Fleurus is expected to begin in mid-2008.
Glucotrace(R) is approved for sale across Europe. About MDS Nordion
MDS Nordion (http://www.mds.nordion.com/) is a world leader in
medical isotopes, radiation and related technologies. It is a
division of MDS Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life
sciences company that provides market-leading products and services
that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has
more than 5,600 highly skilled people in 28 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. DATASOURCE: MDS Nordion CONTACT: Media Inquiries,
Olivia Nixon, MDS Nordion, (613) 592-2790 ext. 2558, (613) 724-1767
(Mobile), ; Investor Inquiries, Sharon Mathers, Vice-President,
Investor Relations and External Communications, (416) 675-6777 ext.
34721,
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Mds (Borsa di New York (NYSE)): 0 articoli recenti
Più Mds Articoli Notizie